MARKSANS PHARMA - Q1 FY 18-19 REVIEW

MARKSANS PHARMA

Q1 FY 18-19 REVIEW

 

CONSOLIDATED REVENUE OF RS.238 CR IN Q1 (221.09 CR), A GROWTH OF 7.87%

EBITDA  WAS RS.38.72 CR (29.03 CR), A GROWTH OF 33.38%

CONSOLIDATED EBIDA WAS 16.23% OF REVENUE

PBT WAS 30.36 CR

PAT AT 25.14 CR (13.64 CR), A GROWTH OF 84.31%

q.EPS stands at 0.58 on FV of Rs.1and on this annualized PE ratio is 15

Maximum exports are to Europe and north America incl USA

Marksans Pharma Limited is engaged  in Research, Manufacturing

& Marketing of generic pharmaceutical  formulation in  the global markets.

The company's manufacturing facilities  are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA.

The company's robust product portfolio spreads over major therapeutic segments of  CVS, CNS, Anti-diabetic, Pain Management, Gastroenterologicals and Anti-allergies.

The company is marketing these products globally. 

MP	35
PE	15
VOLUME	2002748
FV	1
PRICE TREND
14.08.18	1 week	2 week	1 month	3 month	6 month	9 month	1 year
Price	32.55	28.1	26.05	27.45	40.85	41.85	40.45
Gain / Loss	-5.99%	8.90%	17.47%	11.48%	-25.09%	-26.88%	-24.35%

IOL CHEMICALS AND PHARMACEUTICALAS LTD - Q1 FY 18-19 REVIEW

IOL CHEMICALS AND PHARMACEUTICALAS LTD

Q1 FY 18-19 REVIEW

IOL CHEMICALS AND PHARMACEUTICALS , a leading manufacturer of APIs/Bulk drugs and speciality chemicals has reported strong performance in Q1 FY 19

Net revenue increased by 68% to 362 Cr

EBITDA increased by 57% to 43.43 cr

Net profit increased by 384% from 2.98 cr to 14.41 Cr

Exports increased by 88% to Rs.147 cr

Annual capacity of Ibuprofen increased by 39% to 10,000 MT.

EPS on a FV of Rs.10 is 2.56 against 0.53 year ago. 

At the current Market price of 124,PE works out to 12.1

Volume of transactions is good around 243670.

Price trend indicates that price has increased from 66 to 124 in a period of 1 year, with an 87% increase.

The company has also launched various APIs in anti-diabetic, anti-cholestoral, and anti-platelets which are getting good response.

Its product profuile includes APIs, Ibuprofen, Metformin, Fenofibrate, Clopidogrel, Lamotrigene and speciality chemicals such as Ethyl Acetate, Iso Butyl Benzene, Mono chloro acetic acid and acetyl chloride

It is the world’s largest producer of Ibuprofen with 10,000 TPA capacity. And having backward integrated manufacturing facility at a single location. It has DSIR approved R&D facility.

Overseas customers are spread across, Australia, Belgium, Hungary, spain, Switzerland,Portugal, Poland, ireland, USA, Chile, Peru, Brazil, Argentina, Colombia, Mexico, Indonesia, south korea, Thailand, Iran etc.

Products are sold generally to Branded Generic formulators.

IOL CHEMICAL	Jun '18	Mar '18	Dec '17	Sep '17	Jun '17	YOY	QOQ
Net Sales	361.84	287.52	262.68	217.79	215.31	68.06	25.85
P B T	19.67	12.73	9.56	5.84	3.17	520.5	54.52
Tax	5.26	1.24	0.76	1.41	0.19	2668.42	324.19
Net Profit	14.41	11.49	8.8	4.43	2.98	383.56	25.41
Equity	56.21	56.21	56.21	56.21	56.21	0	0
Diluted EPS	2.56	2.05	1.56	0.79	0.53	383.02	24.88
MP	124
PE	12.1		M CAP	695 CR
FV	10		BV	38.38
VOLUME	243,670
PRICE TREND
28.08.18	1 week	2 week	1 month	3 month	6 month	9 month	1 year
Price	119.9	114.55	97.8	97.5	77.95	81.6	66.05
Gain	3.04%	7.86%	26.33%	26.72%	58.50%	51.41%	87.06%